<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105892">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01889862</url>
  </required_header>
  <id_info>
    <org_study_id>165-302</org_study_id>
    <nct_id>NCT01889862</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Evaluate the Efficacy &amp; Safety of Self-Administered Subcutaneous Injections of BMN 165 in PKU Adults Who Have Previously Been Exposed to BMN165</brief_title>
  <acronym>Prism302</acronym>
  <official_title>A Three-Part, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self Administered by Adults With Phenylketonuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BMN 165 clinical development program has been designed to demonstrate the safety and
      efficacy of BMN 165 in reducing blood Phe concentrations in adults with PKU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study BMN 165-302 is a Phase 3, 3 Part/4 armed, Randomized, Double-Blind,
      Placebo-Controlled, Discontinuation Study to Evaluate the Efficacy and Safety of Self
      Administered Subcutaneous Injections of BMN 165 by Adults With PKU.

      In contrast to BMN study 165-301 (currently recruiting) which is open to adults who are
      naive to BMN165, this study is open only to adults who have been exposed to BMN165 in a
      previous study.

      Study BMN 165-302 is a three-part, Phase 3 study.

      Part 1 is an open-label run-in period designed to stabilize the dosing regimen of subjects
      who enroll from a previous BMN 165 study.

      Part 2 is a double-blind, placebo-controlled, four-arm, discontinuation study designed to
      compare the blood Phe concentrations of subjects who continue administration with BMN 165
      versus those of subjects who temporarily receive placebo.

      Part 3 is a long-term, open-label extension study designed to evaluate the long-term
      efficacy and safety of BMN 165 and to provide long-term access to BMN 165 (no placebo).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events experienced by subjects.</measure>
    <time_frame>Weekly throughout study, an expected average of 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjects will be assessed weekly for adverse events, including laboratory abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma phenylalanine level at Part 2 Week 8 in subjects on placebo versus BMN 165.</measure>
    <time_frame>Part 2 Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>All subjects will have plasma phenylalanine level assessed at Part 2 Week 8. The comparison will be between subjects on placebo versus subjects on study drug (BMN 165).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive and mood symptoms at Part 2 Week 8 in subjects on placebo versus BMN 165</measure>
    <time_frame>Part 2 Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>ADHD-RS IV and the POMS (Profile of Mood States) will be used to evaluate cognitive and mood symptoms in subjects who self administer BMN 165 (40 or 20 mg/day) compared with subjects who self administer a placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Protein intake as reported by subjects in diet diary</measure>
    <time_frame>Every 4 weeks, an expected average of 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diet diary collected monthly to assess protein intake from medical food and from natural protein. This will evaluate patient compliance to study requirements.</description>
  </other_outcome>
  <other_outcome>
    <measure>Trough plasma concentration (Cmin) of BMN 165</measure>
    <time_frame>Part 2 Week 1, 4 and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Trough plasma concentrations of BMN 165 in subjects during Part 2 of the study assessed via pre-dose PK blood draw.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma phenylalanine level in Part 3 (long term extension)</measure>
    <time_frame>Every 4 weeks, up to 172 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pre-dose plasma sample drawn to assess the long-term effect of BMN 165 (40 mg/day) on blood Phe concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive and mood symptoms in Part 3 (long term extension)</measure>
    <time_frame>Every 24 weeks, up to 172 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognitive and mood symptoms at Part 2 Week 8 in subjects on placebo versus BMN 165 ADHD-RS IV and the POMS (Profile of Mood States) will be used to evaluate cognitive and mood symptoms in subjects during the long-term extension.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentration of BMN 165 over time in relation to plasma phenylalanine level</measure>
    <time_frame>Part 3 Week 9</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples collected at 4 time points during Part 3 Week 9 to evaluate the multiple-dose PK/PD of BMN 165.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Phenylketonuria (PKU)</condition>
  <arm_group>
    <arm_group_label>BMN165 20mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMN165 20mg/day self-administered daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low Placebo self-administered daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMN165 40mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMN165 40mg/day self-administered daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>High Placebo self-administered daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMN165 20mg/day</intervention_name>
    <description>Two different doses of BMN165 compared to eachother and compared to placebo</description>
    <arm_group_label>BMN165 20mg/day</arm_group_label>
    <other_name>PEG-PAL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMN165 40mg/day</intervention_name>
    <arm_group_label>BMN165 40mg/day</arm_group_label>
    <other_name>PEG-PAL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Low Placebo</arm_group_label>
    <arm_group_label>High Placebo</arm_group_label>
    <other_name>Dextran 40</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Individuals eligible to participate in this study must meet all of the following criteria:

          -  Have completed at least 14 weeks of administration with BMN 165 prior to   screening

          -  Have had a stable BMN 165 dose for at least 28 days prior to screening

          -  Are at least 16 years of age and no older than 70 years of age at the time of
             screening

          -  Are willing and able to provide written, signed informed consent after the nature of
             the study has been explained and prior to any research-related procedures; for
             minors, parent or guardian provides written consent and assent may be requested

          -  Are willing and able to comply with all study procedures

          -  For females of childbearing potential, must have a negative pregnancy test at
             screening and be willing to have additional pregnancy tests during the study.
             (Females are considered not of childbearing potential if they have been in menopause
             for at least 2 years, have had a tubal ligation at least 1 year prior to screening,
             or have had a total hysterectomy.)

          -  If sexually active, must be willing to use two acceptable methods of contraception
             while participating in the study

          -  Have maintained their diet (including medical formula) with no significant
             modifications during the 4 weeks prior to randomization and are willing to maintain
             their current diet and, if needed, adjust their dietary and/or medical food protein
             intake according to the study protocol

          -  Have cognitive and linguistic capacities to complete the cognitive and mood
             questionnaires

          -  If applicable, maintained stable dose of medication for ADHD, depression, anxiety, or
             other psychiatric disorder for â‰¥8 weeks prior to enrollment and willing to maintain
             stable dose throughout study unless a change is medically indicated

          -  Are in generally good health, as evidenced by physical examination, clinical
             laboratory evaluations (hematology, chemistry, and urinalysis), and ECG tests
             performed at screening

        Exclusion Criteria:

        Individuals who meet any of the following exclusion criteria will not be eligible to
        participate in the study:

          -  Use of any investigational product (except BMN 165) or investigational medical device
             within 30 days prior to screening or requirement for any investigational agent prior
             to completion of all scheduled study assessments

          -  Use of any medication (except BMN 165) intended to treat PKU, including the use of
             large neutral amino acids, within 2 days prior to the administration of study drug
             (Day 1, first dose of BMN 165)

          -  Have known hypersensitivity to any component of BMN 165

          -  Have known hypersensitivity to Dextran or components of Dextran

          -  Use or planned use of any injectable drugs containing PEG (other than BMN 165),
             including medroxyprogesterone injection, within 3 months prior to screening and
             during study participation

          -  Current use of levodopa

          -  A positive test for HIV antibody, hepatitis B surface antigen, or hepatitis C
             antibody (subjects without screens during previous BMN 165 study)

          -  A history of organ transplantation or on chronic immunosuppressive therapy

          -  A history of substance abuse (as defined by the DSM IV) in the past 12 months or
             current alcohol or drug abuse

          -  Current participation in the Kuvan registry study (PKU Demographics, Outcomes and
             Safety [PKUDOS]). Patients may discontinue the PKUDOS registry trial to allow
             enrollment in this study

          -  Pregnant or breastfeeding at screening or planning to become pregnant (self or
             partner) or breastfeed at any time during the study

          -  Concurrent disease or condition that would interfere with study participation or
             safety (eg, history or presence of clinically significant cardiovascular, pulmonary,
             hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,
             neurological, oncologic, or psychiatric disease)

          -  Major surgery planned during the study period

          -  Any condition that, in the view of the investigator, places the subject at high risk
             of poor treatment compliance or terminating early from the study

          -  Alanine aminotransferase (ALT) concentration &gt;2 times the upper limit of normal.

          -  Creatinine at least 1.5 times the upper limit of normal
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Merilainen, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego School of Medicine</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>3606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Children's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville, Kosair Charities Pediatric Clinical Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Center for Applied Research Sciences</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Health Systems</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Houston Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unversity of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pku.com</url>
    <description>BioMarin sponsored PKU educational/community website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PKU</keyword>
  <keyword>PEG-PAL</keyword>
  <keyword>Prism</keyword>
  <keyword>BioMarin</keyword>
  <keyword>rAvPAL-PEG</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
